FINWIRES · TerminalLIVE
FINWIRES

$CANF

3 stories mentioning CANFUpdated just now

Every FINWIRES story that references CANF, newest first.

Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) eased 0.2%.In corporate news, short seller Culper Research said Wednesday it has taken a short position in Tarsus Pharmaceuticals (TARS), alleging the commercialization of Xdemvy relies on a Medicare copay assistance structure that "raises serious Anti-Kickback Statute concerns." Tarsus shares were down 3.6%.Can-Fite BioPharma (CANF) shares surged 56% after it said its phase 2a trial of Namodenoson in advanced pancreatic cancer met its primary safety endpoint and showed durable survival in a subset of heavily pretreated patients.Hims & Hers Health (HIMS) shares jumped past 8% after BofA Securities raised its price target to $36 from $25, while keeping its neutral rating.BridgeBio Pharma (BBIO) has raised up to $1 billion in convertible preferred equity led by Sixth Street, with participation from HealthCare Royalty, a KKR (KKR) business, to fund upcoming product launches and pipeline development. BridgeBio shares were up 0.3%.

$BBIO$CANF$HIMS$TARS
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index increasing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) was 0.1% lower.In corporate news, Hims & Hers Health (HIMS) shares jumped nearly 9% after BofA Securities lifted the company's price target to $36 from $25, while keeping its neutral rating.Can-Fite BioPharma (CANF) shares surged 44% after it said its phase 2a trial of Namodenoson in advanced pancreatic cancer met its primary safety endpoint and showed durable survival in a subset of heavily pretreated patients.BridgeBio Pharma (BBIO) has raised up to $1 billion in convertible preferred equity led by Sixth Street, with participation from HealthCare Royalty a KKR (KKR) business, to fund upcoming product launches and pipeline development. BridgeBio shares were down 0.6%.

$BBIO$CANF$HIMS
Wire

Can-Fite Shares Surge After Pancreatic Cancer Study Showed Durable Survival Outcomes

Can-Fite BioPharma (CANF) shares jumped 43% in Wednesday trading after the company said its phase 2a study of Namodenoson in advanced pancreatic cancer met its primary safety endpoint and showed durable survival in a subset of heavily pretreated patients.The open-label trial enrolled 20 patients with advanced pancreatic ductal adenocarcinoma, an aggressive form of pancreatic cancer, who had progressed after standard treatment, according to a statement.Among eight evaluable patients treated as third-line therapy who survived at least two months after treatment initiation, median overall survival exceeded five months, with 37.5% surviving seven months or longer, according to the company.Can-Fite said it plans to advance Namodenoson into a Phase 2b study combining it with chemotherapy.Price: $4.24, Change: $+1.27, Percent Change: +42.76%

$CANF

Track with the FINWIRES app suite